Related Experiment Video
Updated: Mar 26, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Optimal Anticoagulation Strategy for Cardioversion in Atrial Fibrillation
Philipp Bushoven1, Sven Linzbach1, Mate Vamos1
1Department of Cardiology, Division of Clinical Electrophysiology, JW Goethe University, Frankfurt, Germany.
Insights
Direct oral anticoagulants are now preferred over vitamin K antagonists for preventing stroke during cardioversion in atrial fibrillation patients. These newer agents offer improved handling, efficacy, and safety for restoring normal heart rhythm.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Cardioversion aims to restore sinus rhythm in symptomatic atrial fibrillation patients.
- Cardioversion carries a 1-3% risk of thromboembolism.
- Vitamin K antagonists have been the standard for thromboembolism prevention around cardioversion, despite limited trial data.
Purpose of the Study:
- To evaluate the role of direct oral anticoagulants (DOACs) in stroke prevention during cardioversion for atrial fibrillation.
- To compare the efficacy and safety of DOACs versus vitamin K antagonists in this clinical setting.
Main Methods:
- Review of existing data on the use of three approved DOACs during electrical or pharmacological cardioversion.
- Comparison of DOACs with vitamin K antagonists regarding stroke prevention and bleeding complications.
Main Results:
- DOACs have demonstrated usefulness during cardioversion.
- DOACs show favorable efficacy in stroke prevention.
- DOACs exhibit improved safety profiles concerning bleeding complications compared to vitamin K antagonists.
Conclusions:
- Direct oral anticoagulants are recommended as the preferred therapy over vitamin K antagonists for stroke prevention in non-valvular atrial fibrillation patients undergoing elective cardioversion.
- DOACs offer advantages in handling, efficacy, and safety, making them the preferred choice for cardioversion management.
Abstract:
For many patients with symptomatic atrial fibrillation, cardioversion is performed to restore sinus rhythm and relieve symptoms. Cardioversion carries a distinct risk for thromboembolism which has been described to be in the order of magnitude of 1 to 3 %. For almost five decades, vitamin K antagonist therapy has been the mainstay of therapy to prevent thromboembolism around the time of cardioversion although not a single prospective trial has formally established its efficacy and safety. Currently, three new direct oral anticoagulants are approved for stroke prevention in patients with non-valvular atrial fibrillation. For all three, there are data regarding its usefulness during the time of electrical or pharmacological cardioversion. Due to the ease of handling, their efficacy regarding stroke prevention, and their safety with respect to bleeding complications, the new direct oral anticoagulants are endorsed as the preferred therapy over vitamin K antagonists for stroke prevention in non-valvular atrial fibrillation including the clinical setting of elective cardioversion.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Dysrhythmias VI: Management of Dysrhythmias
Cardiopulmonary Resuscitation IV: Pharmacological Management

